激光减容与药物球囊治疗支架内再狭窄的研究进展
|
摘要
随着技术的进步及器材的发展,血管内支架成形术以其微创、安全有效的特点已被广泛应用于外周动脉疾病的治疗中。随之而来的是支架内再狭窄的出现。而对于治疗支架内再狭窄,避免或减少动脉支架再置入早已成为临床医师的共识。所以,减容理念联合药物涂层球囊或药物洗脱球囊的应用可能才是治疗支架内再狭窄的希望。本文就应用激光减容与药物球囊治疗支架内再狭窄的进展进行综述。
Endovascular stent angioplasty has been widely used in the treatment of peripheral arterial disease because of its minimally invasive,safe and effective characteristics. However,in-stent restenosis becomes a critical problem in clinical practice. Volume reduction combined with drug-coated balloon or drug-eluting balloon may be effective treatment methods for in-stent restenosis. This article reviewed the progresses of laser ablation volume reduction and drug balloon in the treatment of in-stent restenosis.
Endovascular stent angioplasty has been widely used in the treatment of peripheral arterial disease because of its minimally invasive,safe and effective characteristics. However,in-stent restenosis becomes a critical problem in clinical practice. Volume reduction combined with drug-coated balloon or drug-eluting balloon may be effective treatment methods for in-stent restenosis. This article reviewed the progresses of laser ablation volume reduction and drug balloon in the treatment of in-stent restenosis.
引文
[1] He Y,Jiang Y,Wang J,et al. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing,China[J]. J Vasc Surg,2006,44(2):333-338. DOI:10. 1016/j. jvs. 2006. 03. 032.
[2] Laird JR,Katzen BT,Scheinert D,et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery:twelve month results from the RESILIENT randomized trial[J]. Circ Cardiovasc Interv,2010,3(3):267-276. DOI:10. 1161/CIRCINTERVENTIONS. 109. 903468.
[3] Manzi M, Cester G, Palena LM. Paclitaxel-coated balloon angioplasty for lower extremity revascularization:a new way to fight in-stent restenosis[J]. J Cardiovasc Surg(Torino),2010,51(4):567-571.
[4] Rundback JH,Herman KC,Patel A. Superficial femoral artery intervention:creating an algorithmic approach for the use of old and novel(endovascular)technologies[J]. Curr Treat Options Cardiovasc Med,2015,17(9):400. DOI:10. 1007/s11936-015-0400-3.
[5]符伟国,岳嘉宁.股腘动脉段病变支架内再狭窄的腔内治疗策略分析[J].中华外科杂志,2016,54(8):586-590. DOI:10.3760/cma. j. issn. 0529-5815. 2016. 08. 006.Fu WG,Yue JN. Analysis of endovascular treatment strategies on in-stent restenosis of femoropopliteal artery lesions[J]. Chinese Journal of Surgery,2016,54(8):586-590. DOI:10. 3760/cma.j. issn. 0529-5815. 2016. 08. 006.
[6] Tosaka A,Soga Y,Iida O,et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coil Cardiol,2012,59(1):16-23. DOI:10. 1016/j. jacc. 2011. 09. 036.
[7]刘巍,周玉杰,赵迎新,等.新型准分子激光在复杂冠状动脉病变介入治疗中的应用[J].中国医药,2018,13(4):504-507.DOI:10. 3760/cma. j. issn. 1673-4777. 2018. 04. 007.Liu W,Zhou YJ,Zhao YX,et al. Application of excimer laser coronary atherectomy in complex coronary intervention[J]. China Medicine,2018,13(4):504-507. DOI:10. 3760/cma. j. issn.1673-4777. 2018. 04. 007.
[8] Dippel EJ,Makam P,Kovach R,et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis:initial results from the EXCITE ISR trial(EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)[J]. JACC Cardiovasc Interv,2015,8(1 Pt A):92-101. DOI:10. 1016/j. jcin. 2014.09. 009.
[9] Schmidt A,Zeller T,Sievea H,et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment:twelve-month results from the PATENT study[J]. J Endovasc Ther,2014,21(1):52-60. DOI:10. 1583/13-4538R. 1.
[10] Laird JR,Yen KK,Rocha-Singh K,et al. Exeimer laser with adjunctive balloon angioplasty and hepafin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis:twelve month results from the SALVAGE study[J].Catheter Cardiovasc Interv,2012,80(5):852-859. DOI:10.1002/ccd. 23475.
[11] Idemoto A,Okamoto N,Tanaka A,et al. Impact of angioscopic evaluation for femoropopliteal in-stent restenosis before and after excimer laser atherectomy[J]. Vasc Endovascular Surg,2017,51(5):335-337. DOI:10. 1177/1538574417707900.
[12] Yamaji K,Ueno M,Yamamoto H,et al. Backyards of chronic total occlusion:scenery revealed through angioscope[J]. Circulation,2014,129(25):2715-2716. DOI:10. 1161/CIRCULATIONAHA. 114. 009978.
[13] Armstrong EJ,Thiruvoipati T,Tanganyika K,et al. Laser atherectomy for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther,2015,22(4):506-513. DOI:10. 1177/1526602815592133.
[14] Cortese B,Silva OP,Agostoni P,et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection[J].JACC Cardiovasc Interv,2015,8(15):2003-2009. DOI:10.1016/j. jcin. 2015. 08. 029.
[15] Rittger H,Brachmann J,Sinha AM,et al. A randomized,multicenter, single-blinded trial comparing paclitaxel-coated balloon angio-plasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study[J]. J Am Coll Cardiol,2012,59(12):1377-1382. DOI:10. 1016/j. jacc. 2012. 01. 015.
[16] Scheller B,Clever YP,Kelsch B,et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. JACC Cardiovasc Interv,2012,5(3):323-330. DOI:10. 1016/j. jcin. 2012. 01. 008.
[17] Stabile E,Virga V,Salemme L,et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis[J]. J Am Coll Cardiol,2012,60(18):1739-1742. DOI:10. 1016/j. jacc.2012. 07. 033.
[18] Brodmann M,Keirse K,Scheinert D,et al. Drug-coated balloon treatment for femoropopliteal artery disease:the IN. PACT global study de novo in-stent restenosis imaging cohort[J]. JACC Cardiovasc Interv,2017,10(20):2113-2123. DOI:10. 1016/j. jcin.2017. 06. 018.
[19] Liistro F,Angioli P,Porto I,et al. Paclitaxel-eluting balloon vs.standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries:the DEBATE-ISR study[J]. J Endovasc Ther,2014,21(1):1-8. DOI:10. 1583/13-4420R. 1.
[20] Grotti S,Liistro F,Angioli P,et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries:three-year results of the DEBATE-ISR study[J]. J Endovasc Ther,2016,23(1):52-57. DOI:10. 1177/1526602815614555.
[21] Jia X,Zhang J,Zhuang B,et al. Acotec drug-coated balloon catheter:randomized, multicenter, controlled clinical study in femoropopliteal arteries:evidence from the Aco ArtⅠtrial[J].JACC Cardiovas Interv,2016,9(18):1941-1949. DOI:10.1016/j. jcin. 2016. 06. 055.
[22] Cassese S,Ndrepepa G,Kufner S,et al. Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries:a meta-analysis[J]. Eurolntervention,2017,13(4):483-489.DOI:10. 4244/EIJ-D-16-00735.
[23] Gandini R,Del Giudice C,Merolla S,et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drugeluting balloon angioplasty in patients with critical limb ischemia:a single-center, prospective, randomized study[J]. J Endovase Ther,2013,20(6):805-814. DOI:10. 1583/13-4308MR. 1.
[24] Inoue S,Koyama H,Miyata T,et al. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease[J]. J Vasc Surg,2002,35(4):672-678.
[25] van den Berg JC,Pedrotti M,Canevascini R,et al. In-stent restenosis:mid-term results of debulking using excimer laser and drug-eluting balloons:sustained benefit?[J]. J Invasive Cardiol,2014,26(7):333-337.
[26] Schillinger M,Mlekusch W,Haumer M,et al. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions:1-year follow-up[J]. J Endovasc Ther,2003,10(2):288-297. DOI:10. 1583/1545-1550(2003)010 <0288:AAESOD> 2. 0. CO; 2.
[27] Dick P,Sabeti S,Mlekusch W,et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis:initial experience[J].Radiology,2008,248(1):297-302. DOI:10. 1148/radiol.2481071159.
[28] Kokkinidis DG,Hossain P,Jawaid O,et al. Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1-year outcomes for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther,2018,25(1):81-88. DOI:10.1177/1526602817745668.
[29] Sixt S,Carpio Cancino OG,Treszl A,et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries[J]. J Vasc Surg,2013,58(3):682-686. DOI:10. 1016/j. jvs. 2013. 02. 019.
[30] Shammas NW. Femoropopliteal in-stent restenosis:gaining ground with excimer laser and drug-coated balloons[J]. J Endovasc Ther,2018,25(1):89-91. DOI:10. 1177/1526602817749587.
[2] Laird JR,Katzen BT,Scheinert D,et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery:twelve month results from the RESILIENT randomized trial[J]. Circ Cardiovasc Interv,2010,3(3):267-276. DOI:10. 1161/CIRCINTERVENTIONS. 109. 903468.
[3] Manzi M, Cester G, Palena LM. Paclitaxel-coated balloon angioplasty for lower extremity revascularization:a new way to fight in-stent restenosis[J]. J Cardiovasc Surg(Torino),2010,51(4):567-571.
[4] Rundback JH,Herman KC,Patel A. Superficial femoral artery intervention:creating an algorithmic approach for the use of old and novel(endovascular)technologies[J]. Curr Treat Options Cardiovasc Med,2015,17(9):400. DOI:10. 1007/s11936-015-0400-3.
[5]符伟国,岳嘉宁.股腘动脉段病变支架内再狭窄的腔内治疗策略分析[J].中华外科杂志,2016,54(8):586-590. DOI:10.3760/cma. j. issn. 0529-5815. 2016. 08. 006.Fu WG,Yue JN. Analysis of endovascular treatment strategies on in-stent restenosis of femoropopliteal artery lesions[J]. Chinese Journal of Surgery,2016,54(8):586-590. DOI:10. 3760/cma.j. issn. 0529-5815. 2016. 08. 006.
[6] Tosaka A,Soga Y,Iida O,et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coil Cardiol,2012,59(1):16-23. DOI:10. 1016/j. jacc. 2011. 09. 036.
[7]刘巍,周玉杰,赵迎新,等.新型准分子激光在复杂冠状动脉病变介入治疗中的应用[J].中国医药,2018,13(4):504-507.DOI:10. 3760/cma. j. issn. 1673-4777. 2018. 04. 007.Liu W,Zhou YJ,Zhao YX,et al. Application of excimer laser coronary atherectomy in complex coronary intervention[J]. China Medicine,2018,13(4):504-507. DOI:10. 3760/cma. j. issn.1673-4777. 2018. 04. 007.
[8] Dippel EJ,Makam P,Kovach R,et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis:initial results from the EXCITE ISR trial(EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis)[J]. JACC Cardiovasc Interv,2015,8(1 Pt A):92-101. DOI:10. 1016/j. jcin. 2014.09. 009.
[9] Schmidt A,Zeller T,Sievea H,et al. Photoablation using the turbo-booster and excimer laser for in-stent restenosis treatment:twelve-month results from the PATENT study[J]. J Endovasc Ther,2014,21(1):52-60. DOI:10. 1583/13-4538R. 1.
[10] Laird JR,Yen KK,Rocha-Singh K,et al. Exeimer laser with adjunctive balloon angioplasty and hepafin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis:twelve month results from the SALVAGE study[J].Catheter Cardiovasc Interv,2012,80(5):852-859. DOI:10.1002/ccd. 23475.
[11] Idemoto A,Okamoto N,Tanaka A,et al. Impact of angioscopic evaluation for femoropopliteal in-stent restenosis before and after excimer laser atherectomy[J]. Vasc Endovascular Surg,2017,51(5):335-337. DOI:10. 1177/1538574417707900.
[12] Yamaji K,Ueno M,Yamamoto H,et al. Backyards of chronic total occlusion:scenery revealed through angioscope[J]. Circulation,2014,129(25):2715-2716. DOI:10. 1161/CIRCULATIONAHA. 114. 009978.
[13] Armstrong EJ,Thiruvoipati T,Tanganyika K,et al. Laser atherectomy for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther,2015,22(4):506-513. DOI:10. 1177/1526602815592133.
[14] Cortese B,Silva OP,Agostoni P,et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection[J].JACC Cardiovasc Interv,2015,8(15):2003-2009. DOI:10.1016/j. jcin. 2015. 08. 029.
[15] Rittger H,Brachmann J,Sinha AM,et al. A randomized,multicenter, single-blinded trial comparing paclitaxel-coated balloon angio-plasty with plain balloon angioplasty in drug-eluting stent restenosis:the PEPCAD-DES study[J]. J Am Coll Cardiol,2012,59(12):1377-1382. DOI:10. 1016/j. jacc. 2012. 01. 015.
[16] Scheller B,Clever YP,Kelsch B,et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. JACC Cardiovasc Interv,2012,5(3):323-330. DOI:10. 1016/j. jcin. 2012. 01. 008.
[17] Stabile E,Virga V,Salemme L,et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis[J]. J Am Coll Cardiol,2012,60(18):1739-1742. DOI:10. 1016/j. jacc.2012. 07. 033.
[18] Brodmann M,Keirse K,Scheinert D,et al. Drug-coated balloon treatment for femoropopliteal artery disease:the IN. PACT global study de novo in-stent restenosis imaging cohort[J]. JACC Cardiovasc Interv,2017,10(20):2113-2123. DOI:10. 1016/j. jcin.2017. 06. 018.
[19] Liistro F,Angioli P,Porto I,et al. Paclitaxel-eluting balloon vs.standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries:the DEBATE-ISR study[J]. J Endovasc Ther,2014,21(1):1-8. DOI:10. 1583/13-4420R. 1.
[20] Grotti S,Liistro F,Angioli P,et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries:three-year results of the DEBATE-ISR study[J]. J Endovasc Ther,2016,23(1):52-57. DOI:10. 1177/1526602815614555.
[21] Jia X,Zhang J,Zhuang B,et al. Acotec drug-coated balloon catheter:randomized, multicenter, controlled clinical study in femoropopliteal arteries:evidence from the Aco ArtⅠtrial[J].JACC Cardiovas Interv,2016,9(18):1941-1949. DOI:10.1016/j. jcin. 2016. 06. 055.
[22] Cassese S,Ndrepepa G,Kufner S,et al. Drug-coated balloon angioplasty for in-stent restenosis of femoropopliteal arteries:a meta-analysis[J]. Eurolntervention,2017,13(4):483-489.DOI:10. 4244/EIJ-D-16-00735.
[23] Gandini R,Del Giudice C,Merolla S,et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drugeluting balloon angioplasty in patients with critical limb ischemia:a single-center, prospective, randomized study[J]. J Endovase Ther,2013,20(6):805-814. DOI:10. 1583/13-4308MR. 1.
[24] Inoue S,Koyama H,Miyata T,et al. Pathogenetic heterogeneity of in-stent lesion formation in human peripheral arterial disease[J]. J Vasc Surg,2002,35(4):672-678.
[25] van den Berg JC,Pedrotti M,Canevascini R,et al. In-stent restenosis:mid-term results of debulking using excimer laser and drug-eluting balloons:sustained benefit?[J]. J Invasive Cardiol,2014,26(7):333-337.
[26] Schillinger M,Mlekusch W,Haumer M,et al. Angioplasty and elective stenting of de novo versus recurrent femoropopliteal lesions:1-year follow-up[J]. J Endovasc Ther,2003,10(2):288-297. DOI:10. 1583/1545-1550(2003)010 <0288:AAESOD> 2. 0. CO; 2.
[27] Dick P,Sabeti S,Mlekusch W,et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis:initial experience[J].Radiology,2008,248(1):297-302. DOI:10. 1148/radiol.2481071159.
[28] Kokkinidis DG,Hossain P,Jawaid O,et al. Laser atherectomy combined with drug-coated balloon angioplasty is associated with improved 1-year outcomes for treatment of femoropopliteal in-stent restenosis[J]. J Endovasc Ther,2018,25(1):81-88. DOI:10.1177/1526602817745668.
[29] Sixt S,Carpio Cancino OG,Treszl A,et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries[J]. J Vasc Surg,2013,58(3):682-686. DOI:10. 1016/j. jvs. 2013. 02. 019.
[30] Shammas NW. Femoropopliteal in-stent restenosis:gaining ground with excimer laser and drug-coated balloons[J]. J Endovasc Ther,2018,25(1):89-91. DOI:10. 1177/1526602817749587.